Adjuvant pazopanib does not PROTECT against recurrence of high-risk, initially localized renal cell cancer but does provide novel insights

Grant D. Stewart, Bradley C. Leibovich, Sylvie Negrier, Robert A. Figlin

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Adjuvant pazopanib does not PROTECT against recurrence of high-risk, initially localized renal cell cancer but does provide novel insights'. Together they form a unique fingerprint.